Indium (111In) biciromab
From WikiMD's WELLNESSPEDIA
| Indium (111In) biciromab | |
|---|---|
| INN | |
| Drug class | |
| Routes of administration | |
| Pregnancy category | N/A |
| Bioavailability | |
| Metabolism | |
| Elimination half-life | |
| Excretion | |
| Legal status | Withdrawn |
| CAS Number | 138783-13-8 |
| PubChem | |
| DrugBank | |
| ChemSpider | none |
| KEGG | D03111 |
Indium (111In) biciromab (INN, trade name FibriScint, developed by Centocor) was a drug targeting fibrin, a protein involved in the clotting of blood.[1] It was the Fab' fragment of a mouse monoclonal antibody labelled with the radioisotope indium-111 for the diagnosis of thromboembolism,[2] but was withdrawn during clinical trials.[3]
References[edit]
- ↑ King, David J.."Recombinant antibodies for the diagnosis and therapy of human disease".Current Opinion in Drug Discovery & Development.1999;2(2)
- 112.
- ↑ Answers.com: Centocor Ortho Biotech Products, L.P.
- ↑ DiagnosticImaging.com: Centocor withdraws imaging agent applications
| Monoclonals for bone, musculoskeletal, circulatory, and neurologic systems | ||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
